0504 GMT January 21, 2022
An Iranian pulmonologist is convinced that COVID-19 pandemic will be over once each country manages to vaccinate 70 percent of its population against the virus causing it.
Speaking in an exclusive interview with Iran Daily, Dr. Farhad Mosadeq, added following an adequate level of public inoculation against the coronavirus, the infectious disease will become a seasonal sickness like influenza, with few cases reported every now and then.
COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first known case was identified in Wuhan, China, in December 2019. The disease has since spread worldwide, leading to an ongoing pandemic.
In Iran the pandemic broke out in late February 2020, infecting over 2.9 million people and killing more than 80,000 ever since.
Mosadeq added the disease will, however, continue to remain a problem but with less severity, noting that depending on the mutations of the virus, new vaccines may be required.
Commenting on COVID-19 vaccines being developed in Iran, he said he believes they are going to be effective.
Mosadeq added the homemade vaccines, particularly the one dubbed ‘COVIran Barakat’, which is in its third clinical trial phase, have not caused any significant side effect in those who have received them and have elicited good Immunogenicity.
Iran is developing a number of COVID-19 vaccines, including COVIran Barakat (being produced by experts at the Execution of Imam Khomeini's Order), Razi COV-Pars (a product of the Razi Vaccine and Serum Research Institute), and Fakhra (being manufactured by the Defense Ministry’s research center formerly headed by nuclear scientist Mohsen Fakhrizadeh who was assassinated in a suspected Israeli-linked terror attack late last year).
In addition, Pasteur Institute of Iran and Cuba's Finlay Vaccine Institute are jointly developing a COVID-19 vaccine.
The COVIran Barakat vaccine went into human trial on December 29, 2020, after it successfully completed the initial steps, including tests on animals, and obtaining necessary approvals.
The third stage in the clinical trial of the vaccine began in late April.